Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
| Autor: | Monika Parisi, Corey Pelletier, Ali McBride, Qian Cai, Machaon Bonafede, Manish Patel, Oth Tran, Nicole Princic |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Time Factors Filgrastim Organoplatinum Compounds Paclitaxel FOLFIRINOX Leucovorin Deoxycytidine Drug Costs Polyethylene Glycols Cohort Studies 03 medical and health sciences 0302 clinical medicine Cost of Illness immune system diseases Albumins Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Metastatic pancreatic cancer medicine Humans Pharmacology (medical) Neoplasm Metastasis General Pharmacology Toxicology and Pharmaceutics Aged Retrospective Studies Nab-paclitaxel business.industry Treatment options Health Care Costs General Medicine Middle Aged Gemcitabine Recombinant Proteins Pancreatic Neoplasms 030104 developmental biology 030220 oncology & carcinogenesis Antiemetics Camptothecin Female Fluorouracil business medicine.drug |
| Zdroj: | Expert Review of Clinical Pharmacology. 10:1153-1160 |
| ISSN: | 1751-2441 1751-2433 |
| Popis: | The economic burden of metastatic pancreatic cancer (mPC) is substantial while treatment options are limited. Little is known about the treatment patterns and healthcare costs among mPC patients who initiated first-line gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-P + G) and FOLFIRINOX.The MarketScan® claims databases were used to identify adults with ≥2 claims for pancreatic cancer, 1 claim for a secondary malignancy, completed ≥1 cycle of nab-P + G or FOLFIRINOX during 4/1/2013 and 3/31/2015, and had continuous plan enrollment for ≥6 months pre- and 3 months after the first-line treatment. Duration of therapy, per patient per month (PPPM) costs of total healthcare, mPC-related treatment, and supportive care were measured during first-line therapy.550 mPC patients met selection criteria (nab-P + G, n = 294; FOLFIRINOX, n = 256). There was no difference in duration of therapy (p = 0.60) between nab-P + G and FOLFIRINOX. Compared with FOLFIRINOX, patients with nab-P + G had higher chemotherapy drug costs but lower treatment administration costs and supportive care costs (all p 0.01).Patients treated with nab-P + G (vs FOLFIRINOX) had similar treatment duration but lower costs of outpatient prescriptions, treatment administration and supportive care. Lower supportive care costs in the nab-P + G cohort were mainly driven by lower utilization of pegfilgrastim and anti-emetics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|